Matches in Wikidata for { <http://www.wikidata.org/entity/Q66064794> ?p ?o ?g. }
Showing items 1 to 51 of
51
with 100 items per page.
- Q66064794 description "clinical trial" @default.
- Q66064794 description "ensayu clínicu" @default.
- Q66064794 description "klinisch onderzoek" @default.
- Q66064794 description "клінічне випробування" @default.
- Q66064794 name "Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis" @default.
- Q66064794 name "Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis" @default.
- Q66064794 type Item @default.
- Q66064794 label "Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis" @default.
- Q66064794 label "Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis" @default.
- Q66064794 prefLabel "Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis" @default.
- Q66064794 prefLabel "Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis" @default.
- Q66064794 P1050 Q66064794-56E43037-5698-4A5C-8E8E-B26BB9132477 @default.
- Q66064794 P1050 Q66064794-7059D3BD-6888-4D42-A5F2-91E809A0D862 @default.
- Q66064794 P1132 Q66064794-6960B32F-18BC-4E53-8A71-8B95378F4D86 @default.
- Q66064794 P1476 Q66064794-189F9E2D-2AE0-41A9-A024-A736F67AB0C1 @default.
- Q66064794 P17 Q66064794-17AD8359-585F-4015-AA7E-CE263A2BBF60 @default.
- Q66064794 P17 Q66064794-2F22C5DA-741B-42D2-8F48-690F0BBF7CDF @default.
- Q66064794 P17 Q66064794-3F5682D0-7B86-4183-9E96-B37909565819 @default.
- Q66064794 P17 Q66064794-563E87E5-164B-41D7-937D-3DE500B771F2 @default.
- Q66064794 P17 Q66064794-875A618B-8DFF-4EA4-91FF-DB97DB0A55A0 @default.
- Q66064794 P17 Q66064794-CF2013B9-A821-4340-A356-12ED623897FE @default.
- Q66064794 P17 Q66064794-D0D21C0A-9A56-4012-97AF-3E75500F63AC @default.
- Q66064794 P17 Q66064794-EC921961-044D-4548-97F3-2B46820ABE40 @default.
- Q66064794 P17 Q66064794-F2D97165-6BD6-4FBC-BD24-E97A662A7C83 @default.
- Q66064794 P2899 Q66064794-1C026A85-DF55-4FF5-946E-1A65999F3105 @default.
- Q66064794 P3098 Q66064794-ECDFA7E0-7A96-455C-9D6F-B32ACCF81FD8 @default.
- Q66064794 P31 Q66064794-CB77FD40-1753-4C74-8F87-CE90FB9B0946 @default.
- Q66064794 P580 Q66064794-0980EDAB-6B35-4522-9595-35AA6F662219 @default.
- Q66064794 P582 Q66064794-8DCF73CB-E4E6-4E64-AAB9-7641402C0F2B @default.
- Q66064794 P6099 Q66064794-71E693E6-1053-4C09-AE94-899D8974CB06 @default.
- Q66064794 P8363 Q66064794-1DFAC23D-5981-48F6-873E-6F14F1AB8F82 @default.
- Q66064794 P1050 Q229256 @default.
- Q66064794 P1050 Q988594 @default.
- Q66064794 P1132 "+750" @default.
- Q66064794 P1476 "A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis" @default.
- Q66064794 P17 Q145 @default.
- Q66064794 P17 Q16 @default.
- Q66064794 P17 Q183 @default.
- Q66064794 P17 Q211 @default.
- Q66064794 P17 Q29 @default.
- Q66064794 P17 Q30 @default.
- Q66064794 P17 Q36 @default.
- Q66064794 P17 Q37 @default.
- Q66064794 P17 Q55 @default.
- Q66064794 P2899 "+12" @default.
- Q66064794 P3098 "NCT03985943" @default.
- Q66064794 P31 Q30612 @default.
- Q66064794 P580 "2019-06-30T00:00:00Z" @default.
- Q66064794 P582 "2021-12-31T00:00:00Z" @default.
- Q66064794 P6099 Q42824827 @default.
- Q66064794 P8363 Q78089383 @default.